Sam Brusco, Associate Editor03.18.24
Welldoc, a digital health company specializing in cardiometabolic health, has earned CE mark certification for its flagship BlueStar mobile app.
The announcement builds on Welldoc’s 11 existing U.S. Food and Drug Administration (FDA) clearances for type 1 and type 2 diabetes management capabilities, including advanced insulin dosing calculators.
Welldoc’s BlueStar digital health solution guides people through living with diabetes using personalized, artificial intelligence (AI)-driven digital coaching and insights. The broader platform has further support for cardiometabolic conditions like weight management and hypertension.
Welldoc partners with health plans, health systems, and employers with the aim of extending care, improving health, and reducing costs.
“We are thrilled to receive the CE mark certification,” said Kevin McRaith, president and CEO at Welldoc. "This milestone is integral to our collaboration with strategic partners in life sciences, as they expand access to innovative digital health solutions and empower a broader population in the EU to better manage their chronic conditions effectively."
The achievement allows the company and its partners to advance digital solutions in the EU, addressing chronic condition needs that are rising globally. The company has an IP portfolio of 43 patents for its advanced AI and first-in-class tech.
Welldoc also has 17 publications focused on the value of combining continuous glucose monitoring (CGM) with AI-powered digital health solutions.
The announcement builds on Welldoc’s 11 existing U.S. Food and Drug Administration (FDA) clearances for type 1 and type 2 diabetes management capabilities, including advanced insulin dosing calculators.
Welldoc’s BlueStar digital health solution guides people through living with diabetes using personalized, artificial intelligence (AI)-driven digital coaching and insights. The broader platform has further support for cardiometabolic conditions like weight management and hypertension.
Welldoc partners with health plans, health systems, and employers with the aim of extending care, improving health, and reducing costs.
“We are thrilled to receive the CE mark certification,” said Kevin McRaith, president and CEO at Welldoc. "This milestone is integral to our collaboration with strategic partners in life sciences, as they expand access to innovative digital health solutions and empower a broader population in the EU to better manage their chronic conditions effectively."
The achievement allows the company and its partners to advance digital solutions in the EU, addressing chronic condition needs that are rising globally. The company has an IP portfolio of 43 patents for its advanced AI and first-in-class tech.
Welldoc also has 17 publications focused on the value of combining continuous glucose monitoring (CGM) with AI-powered digital health solutions.